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Type 2 Diabetes (T2D) is becoming one of the most prevalent diseases in the 
world. With this comes an increased burden in healthcare and a lower quality of life for 
those affected by diabetes. Further, certain populations are more susceptible to T2D than 
others. For example, in the US, the Hispanic population has the second highest rate of 
T2D while those of Caucasian heritage have the lowest rate of T2D. Studies have shown 
that different environment and socioeconomic standing is not enough to explain the 
increased prevalence of diabetes in the Hispanic population. There must be other factors 
involved in disease susceptibility. Specifically, there is evidence that genetic variation 
and the gut microbiome play a role in human health and disease development including in 
T2D. Furthermore, the Hispanic population is the least studied of all populations for 
diabetes. Therefore, we set out to examine these factors that may increase the 
susceptibility for T2D in Hispanic population. To facilitate the studies on these factors, a 
number of new analytical tools were evaluated. 
First, by using a new beadarray chip that was developed by a consortium of 
experts in T2D and other related diseases, a pilot study on the genetic variations of 
Hispanic population with T2D was completed. To determine the adequate size of cohort 
for this study, a reference database of a larger diabetes genetic study was used. Using the 
method of principle components analysis (PCA), it has shown that the genetic 
information obtained from more than 20 participants would have sufficient resolving 
power to determine whether a particular participant was healthy or diseased, providing 
  
sufficient SNP genotypes are included in the PCA analysis. Following this, a genetic 
study was completed on an adult Hispanic population and 26 new SNPs were found to be 
associated with T2D through comparison with reference populations and PCA analysis. 
Future work will involve increasing the size of cohort to validate the identified SNPs and 
to further evaluate the use of SNP genotypes to define the host for studying the host - gut 
microbe relationships.  
Second, recent studies have indicated the gut microbiome that lives in symbiosis 
with the human host can influence our health. More recently, there are evidences that gut 
microbes can also increase the susceptibility for T2D. Extensive work has been done to 
identify the microbes in the gut, but studying the activity of gut microbes is still under 
development. Therefore, we set out to build a simple model of gut microbes aiming to 
explore new ways to measure the activity. Lactobacillus helveticus, a probiotic gram-
positive bacteria was used to build the model. The enzymatic activity of beta-
galactosidase (β-gal) was assayed with a fluorescent substrate called 4-methylumbelliferyl 
β-D-galactopyranoside. To ensure the β-gal assay is compatible with subsequent studies, a 
whole-cell format was adopted. Since no protocol for the selected gram-positive microbe 
was available, the assay was developed by reducing the background noise and brought 
the assay time to one day with a linear dynamic range over two orders of magnitude. To 
validate the results, the β-gal assay was repeated on a different bacterial strain. With the 
developed β-gal assay, building the gut microbe model can continue towards evaluating 
microbe activity in relationship with the host in health and disease. 
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CHAPTER I 
INTRODUCTION 
1.1 What is Type 2 Diabetes? 
Type 2 Diabetes is a common and debilitating disease with the number of those 
affected increasing drastically each year (CDC Health, 2010).The Center for Disease 
Control (CDC) predicts that without preventative steps, one in three individuals in the 
United States will develop the disease (CDC Health, 2010). Thus, it is becoming 
increasingly more important to develop early detection methods and interventions to help 
prevent the rapid rise of this disease. 
Type 2 Diabetes is also called non-insulin dependent or adult-onset diabetes 
because it usually does not require insulin for treatment and is almost always diagnosed 
in adults older than twenty years old. In fact, less than one percent of children are 
diagnosed with Type 2 Diabetes. Further, it accounts for nearly ninety percent of all 
diabetes cases (CDC Diabetes Statistics Report, 2014).  
The disease symptoms and effects are progressive. It can start with consistently 
high levels of glucose introduced into the blood stream leading to slight insensitivity of 
the glucose receptors in the target tissues. This leads to hyperglycemia and increased 
insulin secretion. There can also be β-cell dysfunction that leads to a decrease in insulin 
levels leading to hyperglycemia and insulin resistance. Β-cell dysfunction can be genetic, 
be caused by cell death due to cellular stress inflicted by obesity induced inflammation, 
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or Reactive Oxygen Species caused by glucolipotoxicity. Once this has begun, a viscous 
cycle occurs where increased insulin levels leads to insulin resistance and thus consistent 
hyperglycemia. This further exacerbates the β-cell dysfunction leading to further insulin 
secretion, proliferation of the β-cells to keep up with the demand, and imbalance in other 
metabolic hormones.  This leads to further β-cell dysfunction and worsening of the 
disease into full blown Type 2 Diabetes. Steps can be taken to reduce the hyperglycemia 
and thus reduce the work load on the β-cells and potentially preventing progression of the 
disease. (Cerf, 2013) 
Because there is increased glucose in the blood stream, there are symptoms of 
increased thirst, weight loss, and longer healing time. Often people go for some time 
ignoring these symptoms before getting diagnosed. It is believed that there are around 
seven million people in the US that have not been diagnosed, but have the disease. Late 
diagnosis as well as poor management can lead to worsening of the disease and an 
increased chance for peripheral effects. These include heart disease, stroke, blindness, 
poor circulation leading to limb amputation, and death. Type 2 Diabetes is currently the 
seventh leading cause of death in America (CDC Diabetes Statistics Report, 2014). 
Nearly a third of the adult US population and half of the elderly population over 
65 has prediabetes. This involves slight insulin resistance with the consequential slight 
increase in blood glucose levels. For most prediabetic individuals, preventative measures 
such as diet, exercise, and medication can protect them from fully developing Diabetes. 
Although Type 2 Diabetes is manageable, it is better to catch it early and to take 
preventative measures to avoid the disease and the many potential side effects it causes.
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1.2 Environment vs. Genetics 
Just as the mode of how the disease starts varies, Type 2 Diabetes is a 
multifactorial disease that has multiple potential sources for susceptibility and 
development. The most commonly associated risk factor for Type 2 Diabetes is 
environmental causes like obesity and poor diet and exercise. However, more recent 
research has indicated that environment alone is not enough to cause diabetes (Lusis et 
al., 2008). Specifically, genetics can change susceptibility for Type 2 Diabetes and the 
gut microbiome, which interacts with the diet and environment, can influence the host 
towards obesity and insulin resistance.  
1.2.1 Genetics and Susceptibility for Type 2 Diabetes 
There has been considerable evidence that supports the fact that innate genetics 
plays a role in the development of diabetes. The most common genetic biomarkers when 
studying this are single nucleotide polymorphisms (SNPs). These are single base 
mutations in the genome that have to occur in at least 1% of the population to be 
categorized as a SNP and not a random mutation The impact of these single base changes 
range from basic appearance changes to significant likelihood of disease development 
(Broad Institute, 2013). To date, there have been at least 88 SNPs associated with Type 2 
Diabetes susceptibility (Mohlke & Boehnke, 2015) with more discovered regularly. Thus 
it has been shown that there is not a single mutation that causes the disease, but rather a 
large number of small changes that have an additive effect that leads to increased 
susceptibility for diabetes (Bonnefond et al., 2010). Further, the number of SNPs that 
have been shown to play a role in diabetes indicates that not only is Type 2 Diabetes a 
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complex disease, there may in fact be sub-categories of the disease based on genetics 
(Murea et al., 2012). Therefore it is important to continue studying these genetic factors 
to identify all possible biomarkers and how they group in different people to cause 
disease.  
One might doubt that there is a genetic factor if the effect is so small. To address 
this question, Goldfine et al. set out to examine if family history, and therefore genetics, 
really played a role in increasing the susceptibility for Type 2 Diabetes. Their study 
included healthy participants with and without family history of diabetes. Those 
participants with family history meant that both their parents had Type 2 Diabetes. The 
insulin sensitivity and glucose response were measured at the start of the study and then 
the participants were followed for an average of 25 years to determine if they would 
develop diabetes. By the end of the study, those with family history had a significantly 
greater chance of developing diabetes compared to those without family history. In 
addition, at the start of the study, the family history group had a greater percentage of 
individuals with slight insulin resistance and low glucose sensitivity. Further, when they 
examined the group as a whole at the end of the study, they found that even amongst the 
population that was not obese, there was a significantly greater risk of Type 2 Diabetes 
development for those with family history. Therefore, this supports that there is in fact a 
genetic influence that increases risk for Type 2 Diabetes and in some cases obesity is not 
a necessary factor for developing the disease. If obesity, the most often associated 
environmental factor, is not always the key factor in developing diabetes, then there must 
also be a strong enough genetic effect that can increase susceptibility for the disease. 
5  
Even with the large number of genetic biomarkers identified, there is more study needed 
to identify the mechanism that causes these small genetic changes to lead up to Type 2 
Diabetes and how sets of SNPs can be sub-categorized and interact with other influential 
factors for the disease like the environment and the gut microbes. 
One aspect that makes understanding the influence these SNPs play in diabetes 
development is that they often lie in non-coding regions like introns and upstream or 
downstream from a gene (Imamura & Maeda, 2011). This could be why these genetic 
mutations do not have as big an impact by themselves, but rather have a small effect that 
adds up to disease. One theory is that the SNPs are located in and around genes that play 
a role in either β-cell development and function or in insulin and other hormone signaling 
and sensitivity (Bonnefond et al., 2010). This mode of action would support the 
multifactorial nature of Type 2 Diabetes in that many of these genetic factors could either 
add up enough to cause the disease or influence the system enough to increase 
susceptibility for the disease along with the right environmental factors leading to 
diabetes. From this, it is feasible to imagine that with enough study of these biomarkers, 
disease susceptibility could be identified early and preventative steps taken to avoid 
development of diabetes. With the impact that Type 2 Diabetes is having on human 
health and the economic strain of over $200 billion per year in the US alone for treatment 
(CDC Diabetes Reportcard, 2014), it is essential to continue identifying the genetic 
biomarkers and mechanisms to prevent the disease from continuing to increase and to 
develop new therapies that are specific for the sub-category of Type 2 Diabetes to reduce 
the risk of complications and improve quality of life. 
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1.2.2 Gut Microbiome 
When thinking about environmental factors that increase risk for Type 2 Diabetes, 
a more recent discovery is that the gut microbiome influences human health through its 
symbiotic relationship with the human host. The microbiome includes a diverse 
collection of microbes in and on the human body with the number of bacterial cells 
outnumbering human cells (Kelvin et al., 2012). Thus these microbes must be essential to 
human life and function. In fact, the impact of the discovery of the human microbiome 
lead to the development of the Human Microbiome Project (The NIH HMP Working 
Group, 2009), which was created to identify all the microbes living in symbiosis with 
humans.  
Within the gut, there is an equally diverse collection of hundreds of microbes in 
different ratios with one another and each individual has a unique collection in their gut 
(Qin et al., 2010). Thus far, it is understood that the gut microbes are essential to human 
function. They support the development and regulation of the immune system, produce 
essential vitamins and nutrients, influence the energy balance in digesting food, and also 
impact how drugs are metabolized (Kinross et al., 2011). Further, an imbalance in the gut 
microbiome, called a dysbiosis, can influence towards obesity, metabolic syndrome, and 
systemic inflammation, all factors likely to play a role in diabetes development (Woting 
& Blaut, 2016). In fact, there has been enough information to suggest there is a link 
between Type 2 Diabetes and the Gut Microbiome that the American Diabetes 
Association held a special session conference on the topic to further the discussion and 
research in this field (Semenkovich, et al., 2015). Overall, the potential interactions 
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between the gut microbiome and the host are beginning to be understood. The gut 
microbiome can positively or negatively influence human health and a dysbiosis of the 
microbiome can lead to a variety of health issues including diabetes and autoimmune 
disorders. That is, because the gut microbes regulate the immune system, they can 
increase or decrease inflammation, which could affect the gut environment as well as 
periphery tissues like the β-cells in the pancreas. Further, the energy balance is influenced 
by the gut microbes and therefore they can influence how nutrients and calories are taken 
in and used. There is even evidence to suggest that certain microbes can influence 
towards obesity even with a healthy diet (Woting & Blaut, 2016). Thus understanding the 
activity of specific microbes could further elucidate the mechanisms involved in disease 
development and how to regulate the gut microbe environment to prevent or treat 
diabetes and related disorders.   
1.3 A Survey of Current Detection Methods 
In order to understand how genetics and the gut microbes plays a role in Type 2 
Diabetes, the ideal detection methods for biomarkers and function needs to be 
determined. There are a variety of options for measuring these two factors. Therefore, 
understanding which methods will provide the most information while keeping cost down 
will be the most effective choice for detecting causes of diabetes susceptibility.  
1.3.1 High-throughput Detection of Genetic Biomarkers 
Technology has advanced to a point that the entire human genome can be 
sequenced in three days (Illumina Sequencing, 2016). Thus genetic data can be measured 
in large scale in a high-throughput manner. When it comes to measuring genetic 
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variation, there are two common options used: whole genome sequencing or genotyping. 
Each has their own benefits and issues. A survey of each follows.  
1.3.1.a Whole Genome Sequencing 
Whole-genome sequencing technology has improved dramatically in the past two 
decades. It is now possible to sequence a human genome for less than $1000 and in less 
than a week. This technology provides the ability to examine the entire genome for all 
potential genetic variations in a person. Further, it allows for detection of mutations that 
are out of the norm like new SNPs and non-SNP mutations like insertions and deletions 
(Illumina Sequencing, 2016). For example, with Illumina’s sequencing technology, 
genomic DNA is isolated and then a sequencing library is created by randomly 
fragmenting the DNA and ligating adapters on the 3’ and 5’ ends. This allows for 
identical primer binding sites for DNA amplification using PCR. The amplified DNA 
fragments are loaded into flow cells that contain complementary oligos that anneal with 
the adapters. Sequencing is performed using a polymerase and fluorescently labeled 
nucleotides which are imaged each time a base is added and the different colors 
associated with specific bases can then be detected in sequence order (Illumina 
Sequencing, 2016).  
The benefit to sequencing is examining all possible variations and getting the 
whole picture of genetic risk for Type 2 Diabetes and other diseases. The downside to 
using whole genome sequencing for SNP detection is also acquiring extra information 
that is not necessarily needed to get an answer to the question being researched. This 
leads to extra cost in time for data processing and analysis as well as extra monetary cost 
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of measuring the entire genome. Thus, unless new mutations are being studied, whole 
genome sequencing is not often used for detecting SNPs associated with disease.  
1.3.1.b Genotyping 
The more common method for SNP detection is called genotyping. In genotyping, 
only the SNP location is measured rather than the entire sequence. This focuses the 
identification of genetic variation to only the target locations. Illumina’s genotyping 
technology uses a type of microarray detection that utilizes microbeads to load the oligos 
on a microchip. Each bead has a specific oligo with a complementary sequence to a target 
SNP. To measure SNPs, the genomic DNA is amplified using Illumina’s proprietary 
amplification technology and then enzymatically fragmented. The DNA is then loaded 
onto the chip and the DNA fragments are allowed to anneal to their complementary 
oligos. The oligo sequence stops one base short of the SNP so that a polymerase can 
complete a single base extension at the SNP location with a fluorescently labeled 
nucleotide. Then the color of the fluorophore is associated with a specific base using 
bioinformatics software (Illumina Genotyping, 2016).  
By only measuring the SNPs there is a significant reduction in data processing 
and analysis as well as cost of materials. Although the amount of time needed to measure 
the data takes about the same amount of time as a whole genome. Genotyping has 
become the standard method used to detect SNPs as long as novel variations are not 
required. There are whole human genome SNPs that cover the majority of single 
nucleotide variations in the human genome as well as custom genotyping arrays for 
targeted and cheaper detection of certain regions of the human genome. The main issue 
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with using genotyping over sequencing is that novel variations cannot be detected and not 
all human SNPs can be placed on a genotyping chip. The issue of coverage is typically 
addressed with bioinformatics tools. In particular, imputation is used to estimate the 
variation present for SNPs not on the chip that have linkage disequilibrium (LD) with 
measured SNPs. LD essentially means that certain SNPs travel together when variation is 
passed down from generation to generation. Therefore, if one SNP is present, it can be 
assumed that those in LD with it will also be present (Wall & Pritchard, 2003). This 
allows for the detection of many SNPs without having the directly measure all of them. 
Although it is an estimation, imputation has become a standard practice to increase 
coverage without increasing cost. Thus, unless it is necessary to detect novel variation, 
genotyping is used for measuring SNPs for association with disease.    
1.3.2 “Omics” for Microbiome Measurements  
In the past, microbial studies involved culturing each strain of microbe and 
studying it extensively. However, this method is no longer applicable when it comes to 
the human gut microbiome. Many of the microbes are very sensitive to different 
environments and therefore cannot be cultured in a lab. Further, the collection of 
microbes is so complex that it would be near impossible to study each individually. 
Therefore a different approach was taken to study the microbiome. It is called “omics” 
and involves identifying a trait about the collection of microbes as a whole. The benefit to 
this is taking real samples and studying their properties as they have been influenced by 
their natural environment. Further, it eliminates the need for culturing or isolating each 
strain of microbe. The most common forms of omics measurements are metagenomics, 
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metatranscriptomics, metaproteomics, and metabolomics. The first is used to identify the 
microbial composition and the latter three are used to detect microbial activity (van 
Baarlen et al., 2013).  
1.3.2.a Microbial Identity and Community Composition 
The initial way the human microbiome was measured was using metagenomics. 
This technique involves isolating the ribosomal RNA (rRNA) to identify the species of 
bacteria. This works because of the unique structure of rRNA in that it has regions of 
constant sequence with variable regions in between. This allows for a simple PCR primer 
design that will anneal to the constant regions while amplifying the variable regions. 
Each variable region is unique to a type of microbe and thus the identity of the microbes 
from the community can be determined as well as the relative abundance using next-
generation sequencing (Morgan & Huttenhower, 2012). The benefit of this method is that 
it is relatively simple to build the sequencing library and it has become standardized with 
Illumina’s sequencing technology, which further streamlines the process (Illumina 
microbes and metagenomics, 2015). Therefore this process has been done extensively on 
many microbiomes including those from many parts of the human body such as the gut 
and skin (Kelvin et al., 2012, Yatsunenko et al., 2012). Further, metagenomics has been 
expanded to also begin building reference genomes of the microbes in the human 
microbiome. However, this is a difficult task since the microbes cannot be easily 
separated from the community and therefore building the whole sequence is time 
consuming and costly. Further, reference genomes only show the potential for activity, 
not activity itself. To date, the majority of microbes in the gut microbiome have been 
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identified and many have reference genomes (Martin et al., 2012). However, that only 
shows who’s there, not what they are doing in the gut environment. Therefore, in order to 
determine how the gut microbiome plays a role in human health and disease, the activity 
or what the microbes are producing needs to be studied and identified. 
1.3.2.b Microbial Activity 
If we look at the potential indicators for activity, the most logical three are the 
mRNA, proteins, and metabolites. Each represents a step in the activity of microbes from 
gene expression, to protein production, to what the proteins produce. Each detection 
target has their pros and cons when studying microbiomes. For example, metabolites are 
typically smaller molecules which can be easily detected using modern spectroscopy 
techniques like mass spectrometry and they provide an accurate image of the activity 
profile of the microbiome. At the same time, although extracting the metabolites does not 
need to maintain biological conditions, isolating all the diverse classes of molecules can 
be time consuming and difficult. Furthermore, the identity of the microbes producing the 
metabolites cannot be traced back and therefore only the activity of the microbiome, not 
the individual microbes, can be detected (Baker, 2011). Proteins, on the other hand, are 
the workhorse of the cell and would show a true and complete depiction of the activity in 
the microbiome. Moreover, proteins can be sequenced and identified by their structural 
components and therefore it is possible to trace the identity of the microbes to the 
activity. However, proteins are difficult to work with and since they are considerably 
larger, they are not as easy to measure as metabolites. Further, protein sequencing is 
complicated in a mixed culture and therefore proteomics is the most labor intensive of the 
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activity measurements (Sven-Bastiaan & Jehmlich, 2016). Finally, mRNA is the gene 
expression and thus represents the image of what proteins are being made. Using mRNA 
for activity detection is the easiest for tracing back to microbes since nucleic acid 
sequencing is well established and high-throughput. Thus metatranscriptomics could 
provide both activity information as well as identity of the microbes. However, RNA is 
highly unstable and easily degraded. Further, mRNA provides only a snapshot of activity 
at the time of collection and multiple proteins can be made from one mRNA so relative 
levels of activity are not as clear (Moran et al., 2013). Since the goal is to determine 
activity in the gut microbiome as it relates to human health and disease development, 
identifying which omics method is most effective will be essential for moving forward 
with understanding the role the gut microbiome plays in Type 2 Diabetes.  
1.4 Specific Aims 
1.4.1 Identifying the Role the Host Plays in Susceptibility 
In order to understand the complexity of Type 2 Diabetes susceptibility, all 
potential factors need to be examined. The first factor that likely plays a role in disease 
development is the genetic code. The genome influences the start of a person’s 
development and phenotypes. If any environmental factor is to be understood, the way 
the genetic variation interacts with the environment needs to be understood first. Hence, 
for studying what the gut microbiome does for human health and disease, the host’s 
genetics must be defined first. The first aim of this study is to complete a pilot study to 
examine the genetic variation that increases susceptibility for Type 2 Diabetes within a 
sub-population. By identifying the genetic patterns that influence disease development, 
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there can be a greater chance of early detection, new treatment, and understanding of the 
mechanisms involved in how these SNPs alter expression pathways in such a way as to 
increase susceptibility for Type 2 Diabetes. 
1.4.2 Building a Simple Model for the Gut Microbiome 
Once the host is defined, it will be possible to assess how the gut microbes 
interact with innate susceptibility towards disease. Due to the complexity of gut 
microbiome, developing a simple model is needed to study their activity and to develop 
new experimental approaches for determining how the gut microbes influence human 
health and disease. Thus the second aim is to build a simple model of the gut microbes 
and optimize an assay for detecting a specific activity in the model system. 
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CHAPTER II 
PRINCIPLE COMPONENTS ANALYSIS OF A REFERENCE DATASET 
2.1 Introduction 
2.1.1 Sample Size for a Pilot Study 
The majority of genetic studies involve hundreds to thousands of participants with 
large groups of researchers completing the task of processing the samples and performing 
bioinformatics based data analysis. However, when beginning a genetic study it is often 
the case that the lab resources are small and there is little preliminary data to support the 
hypothesis being tested. Therefore it is beneficial to complete a pilot study to assess if the 
hypothesis is worth investing in on a large scale. When completing a pilot study it is 
helpful to know the minimum participants necessary to get reliable preliminary results to 
test if there is genetic cause for the disease being studied. This was the first question we 
set out to answer. In order to determine how many participants we needed for our Type 2 
Diabetes pilot study, we went to a reference dataset to mimic pilot study conditions. The 
dataset we chose was the Geneva study, which was a longitudinal study for Type 2 
Diabetes. The study included nearly 6,000 participants with both case and control groups 
as well as nearly 1 million SNPs per sample using the Affymetrix Genome-Wide Human 
SNP Array 6.0. Through the large-scale data analysis, several SNPs were identified for 
Type 2 Diabetes susceptibility mostly in women of European decent (Zeggini, 2008). 
Since this is a validated genetic dataset, it can be used as reference data to isolate smaller 
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groups of the data to see if genetic variation can be detected using statistical tools and 
thus identify how many participants are needed to see some results.  
2.1.2 What is Principle Components Analysis? 
The tool chosen to investigate sample size is called principle components analysis 
(PCA). It uses a statistical algorithm to look for patterns in variation in a dataset. 
Specifically, it projects coordinates along the greatest axis of variation and the 
projections are called principle components (pcs). There can be infinite pcs, but the 
majority of variation is explained using the first few pcs. These pcs can be plotted in a 
biplot and patterns in the variation can be detected by looking at these projections 
(Ringner, 2008). In the past, PCA has been used for genetic studies to examine patterns in 
population structure within a dataset. For example, Tian et al. used PCA to reduce false-
positives in their genetic study. They did this by looking at ancestry specific SNPs to 
adjust their case and control analysis to account for variation between sub-populations. 
That is, by doing PCA on ancestral markers, they were able to adjust the case and control 
groups to reflect their sub-population identity and therefore account for natural variation 
between sub-populations that could normally be seen as relevant to the disease rather 
than difference in ancestry. Therefore, PCA is a useful tool for looking at population 
structure and has been proven to be compatible with genetic data. Thus PCA was chosen 
to analyze the reference dataset for detection of case and control groups based on genetic 
information alone. If the two groups form distinct patterns or populations in PCA using 
the genotypes alone without any other information, that would suggest that they are 
distinct enough to be identified as with or without the disease.  
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2.1.3 Bioinformatics Tools  
Although PCA has been shown to be effective with genetic data, there are limits 
to the amount of data that PCA can handle. Many of the genetic studies that use PCA 
only analyze the ancestry SNPs for population structure and therefore a significantly 
reduced dataset is necessary for PCA analysis. In order to prune such a large dataset like 
that from the Geneva study, a bioinformatics tool is needed to handle the data. A 
common program used is called PLINK (Purcell et al., 2007). It is an open-source 
program that runs on a Linux operating system and has a specific file format that is 
common in genotype studies. PLINK has the capability to modify the data, perform 
quality control measures, and complete analysis using various statistical tests. Thus it can 
be used to isolate smaller subsets of individuals to mimic a pilot study and complete 
measures to prune the data to a workable size for PCA. At the same time, even a pruned 
dataset will be significantly large and can thus create long processing times for a PCA 
program. Therefore a specific PCA program called flashPCA (Abraham & Inouye, 2014) 
was selected since it was designed to work with genetic data and can take PLINK files as 
input files without further processing. Since it was designed to work with larger genetic 
datasets, it also has a faster processing speed and can look at the genotypes for projecting 
the pcs. Thus these tools allowed for assessing the sample size and data pruning 
techniques for developing a genetic based pilot study. 
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2.2 Method 
2.2.1 Data Acquisition and Processing 
Data was obtained from the Geneva Study by submitting a dbGAP project request 
through the National Center for Biotechnology Information (NCBI). The request included 
the name of the principle investigator and affiliated institution, the title of the project, and 
a brief summary of the work to be completed on the data. After the request was approved, 
the data was accessible through a secure login on the NCBI website. Data was 
downloaded onto a computer with a 2 terabyte hard drive and Linux operating system. 
The data was encrypted to make downloading the large dataset easier and to protect the 
sensitive human information. Once downloaded, the data was decrypted using the 
provided protocols (dbGAP, NCBI).  
2.2.2 Isolation of Subsets of Individuals 
A random subset of 100 individuals was removed from the larger data set. This 
set of 100 included 50 individuals with Type 2 Diabetes and 50 without diabetes. To 
ensure the reproducibility of the method, this was repeated two more times to create three 
different sets of 100 individuals each with the same case and control ratio. See Appendix 
A for all plink commands.  
2.2.3 Data Pruning 
To filter the number of SNPs down to a size that is compatible with PCA analysis, 
two methods were tested. First, the data was pruned randomly using linkage 
disequilibrium (LD), which will select one SNP from a set of SNPs that have the same 
LD. That is, a single SNP was chosen at random from those sets of SNPs that travel 
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together when passed down generationally. Second, a chi-squared association analysis 
was used to select only the SNPs that were statistically significant below a 0.05 p-value. 
For equation 1, Oi is the observed frequency and Ei is the expected frequency, which is 
the average of all the observed frequencies. If X2 is above the critical value based on n 
observations, then the null hypothesis can be rejected and the difference in frequency is 
statistically significant and thus the p-value will be below the 0.05 threshold (Miller & 
Miller, 2010). 
 
X2 = ∑ (Oi - Ei)2 / Ei        (Equation 1)  
 
Following this, the phenotype information was removed from both pruned data files so 
the PCA would run blind using only the genotypes to determine the pattern of variation.  
2.2.4 PCA Analysis and Plotting 
Each no-phenotype file was run through flashPCA. The program produced 
principle components (pcs) for the data, which were used to create a PCA biplot using 
XLstat (Addinsoft). Specifically, the first two pcs were plotted in a scatter plot and then 
the points were colored based on case (green) or control (blue). The graphs were then 
assessed for separation of case and control. The process of completing the association 
analysis and PCA was done for the other two sets of 100 individuals.  
2.2.5 Reduction of Sample Size 
To determine if separation of case and control could be achieved with fewer 
samples, the three datasets were each reduced to 50 and 20 individuals. The 50% case 
and 50% control ratio was maintained with the smaller sample sets. Association analysis 
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was completed for each set and then the phenotype was removed from the files using the 
same PLINK commands. Finally, flashPCA was used to determine the pcs, which were 
again plotted using XLstat.  
2.2.6 Further Reduction of SNPs 
Since PCA looks at a set of data for patterns in variation, the lowest limits were 
tested to determine the minimum amount of data required to see separation of the case 
and control groups. The SNPs were systematically reduced by taking sets of SNPs below 
lower thresholds of p-values and creating files for PCA analysis using the “extract” 
command as before. That is, SNPs were taken below a p-value of 0.005, 0.0005, and 
0.00005 in order to take the number of SNPs down to the lowest p-values and therefore 
more statistically significant values. This process was completed for all three sets of 100 
as well as the three sets of 50 and 20 individuals. These reduced sets were run on 
flashPCA and the pcs plotted.  
2.3 Results/Discussion 
2.3.1 Data Processing 
The NIH data approval was completed, which allowed 1 terabyte of data to be 
downloaded onto a 2 terabyte hard drive with a Linux operating system. The data was 
decrypted into a usable format that included PLINK format files. This version of the data 
was used for all further analysis. 
2.3.2 Isolating Small Sample Groups 
The idea behind this project was to mimic a pilot study using data that had already 
been acquired and published with genetic biomarkers for Type 2 Diabetes. This reduces 
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the amount of resources used when starting the project by first testing the methods and 
sample sizes on previously measured genetic data. Genetic studies can be costly due to 
working with human samples and using next-generation sequencing technology. Thus, by 
simulating our pilot study by taking smaller groups of samples from a larger study, the 
process can be tested before continuing on with our samples.  
Three sets of 100 individuals with a 50/50 ratio of healthy and diseased in each 
were isolated from the nearly 6000 individuals in the Geneva study. The samples were 
randomly selected from the study pool and isolated from the larger data using command 
1. The data was then tested and confirmed that all 100 samples with the proper phenotype 
was included in the new data files (data not shown). 
2.3.3 Pruning Methods 
Even with flashPCA, which has an extended capacity as a PCA program to 
accommodate larger genetic data sets, there is still a limit to what the program can 
handle. That is, the number of SNPs available from the chip was just under 900,000 and 
therefore a pruning method to reduce the number of SNPs for PCA analysis was 
necessary. The two methods chosen were meant to be algorithms that are common with 
genetic analysis studies and therefore not outside the norm of how genetic data is 
processed. The first method pruned the data based on LD using command 2 and reduced 
the SNPs to 11,391. The second method used association analysis with command 4 to 
look for statistically significant SNPs based on the comparison between the case group 
and the control group. This process reduced the SNPs to 37,319 below a p-value of 0.05. 
Without using the phenotype information to plot the samples, the three datasets were 
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analyzed with flashPCA. The biplots are shown in Figure 1 with case samples colored 
green and the control samples colored blue. For the LD pruning (Fig 1A), the samples do 
not separate, but rather cluster together into the center. On the other hand, the association 
analysis separated the two groups (Fig 1B) into distinct clusters. Therefore using LD does 
not provide prune the data in such a way as to be able to detect patterns. Since association 
analysis is a statistical method, the data is essentially analyzed for genetic biomarkers and 
then the samples are pruned by their statistical significance. The biplot indicates that 
there is enough genetic variation to support a genetic difference between the case and 
control group and the groups can be separated with only 100 samples, which is much less 
than the 6000 samples in the Geneva study. Thus pilot studies can provide useful 
information with smaller sample sizes to establish initial genetic links to a phenotype or 
disease. Further, the association analysis pruning method was more effective for 
detecting patterns and therefore was used for all future work with PCA. 
 
Figure 1. PCA Biplots of Two Pruning Approaches 
A. 
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 B. 
 
A. LD Pruning. This biplot includes 100 samples and shows the set of SNPs selected 
using LD pruning of the data. There are 11,391 SNPs included in the PCA analysis. 
Green = healthy. Blue = diseased. B. Association Analysis Pruning. This biplot also has 
100 samples with a p-value of below 0.05 as the cutoff value. There were 37,319 SNPs 
included in the PCA analysis. Two Individuals were removed as outliers due to lying 
significantly farther away from the rest of the samples. In both biplots, green is case and 
blue is control. 
 
 
2.3.4 Testing the Reduction of the Data 
After the 100 samples were confirmed to separate into two respective groups in 
the PCA biplot, there were two questions that needed to be addressed. One, could the 
number of samples be further reduced while maintaining the separation seen and two, 
could the number of SNPs put into the PCA analysis be reduced? For the first question, 
sample sizes of even 100 can still be quite large to handle for a small pilot study and 
therefore it would be ideal if fewer samples can be used while still detecting patterns in 
the genetic data. To test this, the three sets of 100 were reduced to 50 and 20 sample sizes 
with the same 50/50 case and control ratio. They were then pruned and analyzed as 
before with the association analysis and the PCA biplots created. The 50 samples had 
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36,528 SNPs and the 20 samples had 32,085 SNPs. Thus the number of SNPs was 
relatively similar between the different sample sizes. Further, the PCA biplots show 
separation between case and control for the 50 samples (Fig 2A) and for the 20 samples 
(Fig 2B). However, the separation is not as distinct for the 20 samples and therefore a 
sample size between 20 and 50 would be ideal for the pilot study. The process was 
repeated on all three sets of 100 samples and the results were confirmed (Fig 1 & 2, 
Appendix B). 
 
Figure 2. Reducing Sample Size 
A. 
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 B. 
 
A. This biplot has 50 individuals with 36,528 SNPs using a p-value of 0.05 as the 
threshold. B. This biplot has 20 individuals with 32,085 SNPs using a p-value of 0.05 as 
the threshold.  In both biplots, green is case and control is blue. 
 
Although association analysis was an effective pruning method, the purpose of 
completing genotyping studies is to identify a small set of SNPs associated with a 
particular disease. Therefore we set out to further reduce the number of SNPs to 
determine if we could see separation of case and control and therefore how effective our 
analysis would be for genetic biomarkers in small sample sets. To systematically reduce 
the number of SNPs, the p-value was reduced by a factor of 10 each time to bring the 
SNPs to the lowest possible number while maintaining group separation. The p-values 
were reduced down to 5 x 10-5 which resulted in approximately a 10-fold reduction in the 
number of SNPs with each reduction in p-value. First, the set of 100 samples was tested 
(Fig 3) and separation was maintained down to the lowest p-value with 23 SNPs. The 
reduction of SNPs was then tested on the set of 50 samples (Fig 4) and the set of 20 
samples (Fig 5). In each of these cases the two groups maintain their separation between 
-2000
-1500
-1000
-500
0
500
1000
1500
-5000 -3000 -1000 1000 3000 5000pc2
pc1
26  
case and control. However, as the number of SNPs reduces to the lowest p-value, the 
samples start to spread out and the two groups look less distinct. This could suggest that 
there is a limit on how little data PCA can manage while creating viable pcs for biplots or 
it could support the idea that there are many SNPs that build up to Type 2 Diabetes and 
there is a limit to how few can be present while maintaining the difference between the 
groups. This process was repeated on the other two sets of samples and the results were 
the same (Fig 3-8, Appendix B). All in all, case and control maintained their separation 
even down to double digit number of SNPs and therefore the association analysis and 
PCA are feasible methods for data analysis in a genetic biomarker pilot study.  
 
Figure 3. Set of 100 Samples with Number of SNPs Reduced 
A. 
-30
-20
-10
0
10
20
30
40
-100 -50 0 50 100
pc2
pc1
27  
B. 
 
C. 
 
PCA biplots are of 100 samples with case green and control blue. A. The p-value is 5 x 
10-3 as the threshold giving 3,032 SNPs for PCA analysis. Two samples were removed as 
outliers. B. P-value of 5 x 10-4 as the threshold with 234 SNPs. C. P-value of 5 x 10-5 as 
the threshold with 23 SNPs. Separation of case and control is maintained for all reduction 
of SNPs. 
-6
-4
-2
0
2
4
6
-10 -5 0 5 10pc
2
pc1
-8
-6
-4
-2
0
2
4
-8 -6 -4 -2 0 2 4 6 8
pc2
pc1
28  
Figure 4. Set of 50 Samples with Number of SNPs Reduced 
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 C. 
 
PCA biplots are of 50 samples with case green and control blue. A. The p-value is  5 x 
10-3 as the threshold giving 3,050 SNPs for PCA analysis. B. P-value of 5 x 10-4 as the 
threshold with 282 SNPs. C. P-value of 5 x 10-5 as the threshold with 23 SNPs. 
Separation of case and control is maintained for all reduction of SNPs. 
 
 
Figure 5. Set of 20 Samples with Number of SNPs Reduced 
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 B. 
 
 C. 
 
PCA biplots are of 20 samples with case green and control blue. A. The p-value is  5 x 
10-3 as the threshold giving 2,444 SNPs for PCA analysis. B. P-value of 5 x 10-4 as the 
threshold with 142 SNPs. C. P-value of 5 x 10-5 as the threshold with 12 SNPs. 
Separation of case and control is maintained for all reduction of SNPs. 
 
 
2.4 Conclusion 
After simulating a pilot study with the Geneva data, we were able to use PCA to 
examine the sample size for a pilot study. The results indicated that between 50 and 20 
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individuals would be sufficient for detecting genetic patterns for disease. Therefore a 
small pilot study to investigate potential SNPs linked to Type 2 Diabetes is feasible. 
Furthermore, the results of this small study would be reliable preliminary data for 
beginning to understand how genetics plays a role in disease development. To confirm 
that, a small set of SNPs was isolated from the larger set by systematically reducing the 
p-values. The smaller the p-value, the more statistically significant and thus this 
technique was a logical approach to mimic the detection of the most relevant SNPs. The 
results indicated that even down to the lowest p-values given in the association analysis, 
the case and control separated. Therefore even small data sets are sufficient for results. 
Future work with this could include examining the use of PCA as a supplement to other 
forms of data analysis in genetic studies and using PCA to further sort or subcategorize 
SNPs for significance. 
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CHAPTER III 
GENETIC BIOMARKERS FOR TYPE 2 DIABETES IN A HISPANIC 
POPULATION 
 Parts of the work presented in Chapter III have been published in Diabetes 
Research and Clinical Practice and is referenced as: Watson AL, Hu J, and Chiu 
NHL (2015). Single Nucleotide Polymorphism in Type 2 Diabetes among 
Hispanic Adults. Diabetes Research and Clinical Practice, 108: e25-e27 
 
3.1 Introduction 
It has been well established that Type 2 Diabetes is a worldwide issue affecting 
people of many cultures and environments. However, different populations are affected 
by Type 2 Diabetes more than others. In particular, Native Americans have the highest 
rate followed by Hispanic, African, and Asian heritage, with Caucasian heritage having 
the lowest rate of the disease (CDC Diabetes Statistics Report, 2014). However, if we 
look at the populations best studied for Type 2 Diabetes, they are mostly European 
Caucasian. Moreover, Hispanics have the second highest rate of Type 2 Diabetes, but 
they are the least studied according to the literature (Fig 6). Thus there is a need to study 
and understand why the Hispanic population suffers disproportionately from Type 2 
Diabetes. Although it might be logical to assume that unique environmental factors are 
increasing Hispanics risk for developing diabetes, early studies showed that obesity, 
caused by the cultural diet, alone could not explain increased diabetes cases (Stern et al., 
1983) nor could socioeconomic status (Chakraborty et al., 1986). In fact, Chakraborty et 
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al. found that with increased socioeconomic standing in a Mexican American population 
usually also coincided with a greater percentage of Caucasian gene markers compared to 
Native American gene markers. At the same time, it is known that Native Americans 
have genetic variations that increase their susceptibility to Type 2 Diabetes (Baier & 
Hanson, 2004) and Mexican American populations are a mixture of Native American and 
European Caucasian (Reed, 1974; Parra et al., 2011). This suggests that environment 
alone cannot explain the increase in susceptibility to Type 2 Diabetes, but rather there is a 
genetic cause that plays a role in disease development for Hispanic populations. Since it 
has been demonstrated that there is a genetic factor that increases Type 2 Diabetes 
susceptibility for Hispanics and there is a need for further study in this population, the 
pilot study for identifying the genetics of the host was completed on Hispanic adults. 
 
Figure 6. Number of Diabetes Studies by Population 
 Search results for studies done specifically for diabetes by population were done using 
the NCBI Pubmed site and was last updated September 2015. As can be seen, the 
European population is the most studied and the Hispanic population is the least studied. 
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3.2 Method 
3.2.1 Sample Selection 
A reasonable sample size of 36 participants was recruited for this pilot study at 
clinics and communities around central North Carolina. Eligibility included self-
identification as of Hispanic descent, at least 18 years of age, and ability to speak Spanish 
or English. Of the 36, there were 18 with Type 2 Diabetes and 18 who did not have Type 
2 Diabetes. IRB approval was completed before starting and all participants gave 
permission to use their de-identified information and blood sample for this study. 
Hispanic adults were interviewed for basic health background and family history of Type 
2 Diabetes as well as tested for HbA1c levels with a cutoff of >6.5% as an indicator of 
diabetes (Tatsch et al., 2012).  Finally, participants provided a blood draw for DNA 
isolation using the PAXgene blood DNA tubes (Qiagen), which were stored at 4oC until 
further processed.  
3.2.2 DNA Isolation and Characterization 
Genomic DNA was isolated from the blood samples using the PAXgene blood 
DNA isolation kit (Qiagen). To isolate the DNA, the blood from the collection tube was 
inverted to mix the blood and then poured into a tube with lysis buffer and mixed by 
inverting the tube 5 times. The mixture was then centrifuged for 5 min at 2500 x g at 
room temperature in a swing-out rotor centrifuge. The supernatant was removed and then 
5 mL of washing buffer was added and the tube vortexed for a few seconds and then 
centrifuged for 3 min at 2500 x g. The supernatant was discarded and then 5 mL of 
digestion buffer with 50 µL PreAnalytiX Protease was added to the tube. The tube was 
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vortexed for 20 sec at high speed to fully dissolve the pellet. Then the mixture was 
incubated in a water bath at 65oC for 10 min. After 5 sec of vortexing, 5 mL of 100% 
isopropanol was added and the tube inverted 20 times until white clumps of DNA were 
visible. The tube was then centrifuged for 3 min at 2500 x g and the supernatant carefully 
discarded. The pellet in the tube was allowed to dry on a piece of kim-wipe for 1 min. 
Then 5 mL of 70% ethanol was added and the tube vortexed for 1 sec followed by 
centrifugation for 3 min at 2500 x g to wash the DNA pellet. The supernatant was 
removed and the pellet was again allowed to dry on a kim-wipe completely for about 5 
min. Finally, 1 mL of resuspension buffer was added and the mixture incubated in a 
water bath at 65oC for 1 hour and then at room temp overnight. Once the DNA was 
thoroughly dissolved, it was stored at -20oC for future use.   
Genomic DNA was characterized for concentration. This was determined using 
PicoGreen fluorescent dsDNA stain and a POLARstar OPTIMA plate reader (BMG 
Labtech). A standard curve was made with double stranded lambda DNA standard in TE 
buffer. The concentrations ranged from 2 µg/mL to 2 ng/mL with a TE buffer blank. 
Equal volumes of standard and PicoGreen reagent were mixed in wells in a 96 well plate. 
The solution was incubated for 2-5 min protected from light and then the fluorescence 
measured with excitation at 480 nm and emission at 520 nm. The blank was subtracted 
from each value and a standard curve was plotted of concentration versus fluorescence. 
For the DNA samples, each was diluted 1:5000 in TE buffer and then mixed with an 
equal volume of PicoGreen reagent in a 96 well plate. The mixture was incubated for 2-5 
min protected from light and then the fluorescence measured as before. The concentration 
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in each diluted sample was determined using the standard curve and then the 
concentration of the original DNA samples were calculated based on the dilution factor. 
Each sample was diluted to 50 ng/µL for loading on the genotyping chip.  
3.2.3 Genotyping 
All 36 samples were genotyped on the Cardio-Metabochip (Illumina) using the 
protocols provided. The Cardio-Metabochip is a genotyping chip designed by a 
consortium of experts in Type 2 Diabetes and other metabolic and cardiovascular 
diseases (Voight et al., 2012). The details of the chip are shown in Table 1. After 
genotyping, the raw fluorescent data from the chip was converted to genotypes for each 
SNP using GenomeStudio (Illumina).  
 
Table 1. The Cardio-Metabochip 
  Fine-mapping Targets Replication SNPs 
Total 
SNPs 
  # Loci # SNPs    
Type 2 Diabetes 34 16,717 5,057 21,774 
Cardio-
Metabochip 257 122,241 63,450 185,691 
 
The SNPs included on the Cardio-Metabochip were selected by a consortium of experts 
on genetic biomarkers for diabetes and related cardiovascular and metabolic disorders. 
Fine-mapping targets are included to explore genes that are suspected to be involved in 
disease traits and replication SNPs are specific variations that have already been 
identified to be associated with a disease.
37  
3.2.4 Data Processing 
There were several tests completed to check for the quality of the data and to 
remove any SNPs or samples that would cause a bias or error to the data analysis. First, 
SNPs were removed if they did not contain any chromosome information since it was 
essential for PLINK to complete the data analysis. At the same time, the data was 
converted to a binary format for faster processing speed. Then phenotypes and genders 
were added into the data to facilitate quality control and analysis. Each text file contained 
the appropriate information in the proper format required by the PLINK program to insert 
the new information into the data files. Finally the participant identification numbers 
were changed to further de-identify the data and to simplify the code for each individual 
to a single number.  
3.2.5 Quality Control 
In order to reduce the possibility of false positives or bias in the data, several 
quality control measures were completed. First, a sex-check was done to ensure there was 
no crossover of samples on the genotyping chip by examining the included gender 
specific SNPs on the chip and cross checking with the sex listed in the data. Second, the 
data was checked for any missing SNPs due to an error during the measurements on the 
genotyping chip. Any missing SNPs were removed with the same command as with the 
missing chromosome information. Finally, the Hardy-Weinberg equilibrium test was 
completed to remove any SNPs that have unusual relatedness between samples due to 
possible relatedness of the participants. 
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3.2.6 Data Analysis 
The data was analyzed using a chi-squared based association analysis in PLINK. 
This produced a list of SNPs and associated p-values. Then the data was converted to a 
format for Haplowview using gPLINK. In Haplowview, the data was uploaded and sorted 
for p-value from low to high. A Manhattan plot was created to view the entire set of data 
and visualize the variation by chromosome. Then the set of SNPs with the lowest p-
values were compared to the Cardio-metabochip supplemental data to determine which 
were chosen for potential association to Type 2 Diabetes. The allelic frequency for each 
of the top associated SNPs was calculated using equation 2 and then the nearest gene for 
each was determined using the dbSNP database from NCBI.  
 
Allelic Frequency = ∑ allele 1 / total alleles     (Equation 2) 
 
 
3.2.7 Comparison to Reference Populations 
Reference populations were collected from the HapMap Program (International 
HapMap Consortium, 2010). Specifically, three populations were used: Hispanic, Central 
European, and Japanese/Chinese. Each of the top 26 SNPs were identified in the 
reference populations and the allelic frequency was recorded. The reference populations 
were considered healthy. Then the allelic frequency of the case group was compared to 
the reference populations by calculating a percent difference using equation 3. 
 
%Diff = │(SAF - RAF)│ / RAF x 100       (Equation 3)
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From equation 3, SAF is the allelic frequency of the sample for the case group and RAF is 
the allelic frequency of the reference group. After the %Diff was calculated for each 
SNP, it was compared to the reference populations. The average and standard deviation 
was calculated and the SNPs with a percent difference above the average were 
highlighted. 
3.2.8 PCA 
The top 26 SNPs were placed in a Microsoft Excel spreadsheet with their allelic 
information. The letters were converted to numbers with 0 being homozygous for the 
ancestral allele, 1 being heterozygous, and 2 being homozygous for the SNP allele. The 
data was then measured using PCA with XLstat and the biplots and coordination plots 
were graphed.  
3.3 Results/Discussion 
3.3.1 Participant Selection 
Based on the PCA data from the reference material, a sample size between twenty 
and fifty participants was acceptable for a pilot study of genetic variation. It was essential 
to have enough participants to be able to detect if there is a genetic factor that increases 
the susceptibility for Type 2 Diabetes in a Hispanic population and therefore we used the 
results from the initial PCA study to determine the number of participants to select. There 
were 36 participants, half of which had Type 2 Diabetes and half who were healthy to 
serve as a control group (Table 2). All were adults with an age range from 19 to 70 and 
about half of them had family history of diabetes. The HbA1c test is used to measure how 
glycosylated the hemoglobin has been over the past 3 months. It is an indicator of how 
40  
concentrated the blood sugar has been for a period of time and is easily measured with a 
small drop of blood. It is standard that an HbA1c of greater than 6.5% is an indicator for 
Type 2 Diabetes (Tatsch, 2012). All participants in the case group had an HbA1c above 
the threshold with an average of 7.61%. Those in the control group were below the 
threshold with an average of 5.47%. This could be deemed a bit high for a control group 
average, however a number of the healthy participants could be classified as pre-diabetic 
based on their HbA1c levels. Since they had only slightly elevated blood sugar levels and 
did not have diabetes at the time of measurement, they were kept in the control group.  
 
Table 2. Participant Demographics 
 Case Controls 
n 18 18 
Sex:   Male 5 4 
Female 13 14 
Age (Mean ± SD) 51 ± 13 43 ± 11 
Age Range 19 - 70 25 - 62 
HbA1C 7.61% ± 
1.31 
5.47% ± 
0.49 
Family History 11 8 
There were 36 participants in the pilot study. Specific information was recorded about 
each individual at the participation interview and is shown in the table above. All 
participants were adults and all those in the case group had an HbA1c above the 6.5% 
threshold. There were about 75% females and 25% males and approximately half of the 
entire group had family history of diabetes. 
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3.3.2 Genomic DNA Isolation 
Each blood sample was extracted for genomic DNA. The kit used for extraction 
was designed specifically for isolating DNA from blood samples. This allows for an 
optimized and quick method for DNA isolation, which is beneficial when working with a 
larger number of samples and with complex biological samples. All blood samples were 
successfully extracted for genomic DNA. Further, determining an accurate DNA 
concentration in each sample was important. This is due to the fact that the genotyping 
chip works within a very specific concentration range. That is, in order for proper 
determination of the genotypes, the amount of DNA loaded on the chip has to be known 
exactly. Therefore, a highly sensitive fluorescent assay was used to determine the 
concentration. The DNA stain used was PicoGreen from ThermoFisher (Fig 7). It is a 
fluorescent stain that is highly selective for double stranded DNA (dsDNA) with nearly a 
thousand fold enhancement in fluorescence upon binding with dsDNA. Thus, even if 
single stranded DNA or RNA is present in the sample, only the concentration of dsDNA 
will be detected.  PicoGreen also has a large linear dynamic range, allowing for detection 
of a variety of concentrations including very low concentrations, making it a very 
sensitive detection method. Using PicoGreen, the concentration of each DNA sample was 
successfully determined (Table 3). The concentrations between samples varied 
significantly. However, that can be explained by two factors. First, the entire blood 
sample was used to extract DNA. Therefore the volume was not measured and varied in 
each blood draw. Second, the DNA is specifically isolated from the white blood cells. 
Since blood is a complex mixture of many cells and compounds, the number of white 
42  
blood cells can vary drastically depending on the person. This variety between each 
sample is enough to cause a wide difference between DNA concentrations. Despite this 
variability in concentration, it is important to note that there was enough DNA isolated 
from each sample except number 8 to be able to get the ideal 50 ng/µL for the genotyping 
chip. Sample 8 was loaded undiluted onto the chip and was able to be measured despite 
the lower concentration.  
 
Figure 7. PicoGreen Structure 
 
PicoGreen has little fluorescence by itself, but has over 1000 fold increase in 
fluorescence upon binding with dsDNA. Further, the structure of the molecule has three 
main components that allows it to selectively bind with dsDNA. The quinolinium group 
intercalates into the DNA, the positive charge on the thiazol electrostatically interacts 
with the negatively charged backbone of the DNA, and the bimethyl aminopropyl groups 
act as arms to interact with the minor groove of the double helix structure to stabilize the 
PicoGreen-dsDNA complex (Dragan et al. 2010).
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Table 3. Genomic DNA Concentration from Human Blood Samples 
Sample 
Number 
Conc. 
DNA 
(ng/μL) 
Sample 
Number 
Conc. 
DNA 
(ng/μL) 
Sample 
Number 
Conc. 
DNA 
(ng/μL) 
Sample 
Number 
Conc. 
DNA 
(ng/μL) 
1 348.4 10 678.7 19 132.2 28 401.9 
2 720.2 11 525.2 20 341.3 29 241.6 
3 92.11 12 517.8 21 443.9 30 99.06 
4 746.8 13 129.1 22 319.6 31 182.0 
5 1114 14 449.1 23 119.6 32 514.3 
6 856.3 15 292.6 24 146.7 33 273.5 
7 253.6 16 191.7 25 564.5 34 151.0 
8 32.50 17 1162 26 304.8 35 1162 
9 1139 18 208.7 27 193.7 36 418.5 
All blood samples were extracted for genomic DNA and then the DNA was characterized 
for concentration using the PicoGreen Assay. All samples except number 8 were diluted 
to 50 ng/µL for genotyping. 
 
3.3.3 Data Preparation for Analysis 
Data was obtained from GenomeStudio (Illumina) in a format specifically for use 
in PLINK. In order to complete the data analysis, certain processing had to be done to the 
raw data to include some phenotypic information and formatting for association analysis. 
First, any SNPs that did not have chromosome information in the MAP file were 
removed using command 10 (Appendix A). The file snplist.txt contained a single column 
list of the SNPs to be removed, which PLINK used as a reference to complete the 
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command. The “make-bed” option converts the data to a binary format, which combines 
the data into a new layout as well as converts the genotypes to a binary code. This format 
allows for a reduction in processing time for each new command and so it was 
maintained for the rest of data processing and analysis.  
The next set of processes added all the necessary phenotype information since the 
raw data from the chip did not contain any. Command 11 and 12 had a related text file 
which contained the family ID, the individual ID, and then the phenotype or gender 
respectively. The phenotype was listed as either positive or negative for Type 2 Diabetes. 
The gender information was essential for completing one of the quality control checks 
and the phenotype was needed for the case-control association analysis. Finally, the 
individual ID was updated to further de-identify the samples and to simplify the code 
associated with each participant for easier note taking using command 13. 
 
Table 4. Quality Control Results 
Quality Control Test 
# SNPs 
Removed 
Chip-reading error 50,261 
Sex-Check 0 
Hardy-Weinberg Equilibrium 2807 
Total SNPs Available for Analysis: 132,623 
Three different measures were used to complete quality control assessments on the 
genotyping data in order to reduce potential bias or errors in the data analysis. Both SNPs 
45  
and samples were assessed for quality, but only SNPs were removed due to failing a 
quality control test.  
 
3.3.4 Quality Control 
When using a statistical tool to analyze a data set, it is important to perform 
quality control measures to remove potential sources of error or bias in the data that could 
result in a false-positive. The measures chosen checked for crossover contamination, 
errors due to the genotyping process, and bias that could be introduced due to relatedness 
of the participants to one another. This way both the measurements and the inherent 
genetics are controlled for error.  
The first check was a “sex-check” using command 14. This produces a list of 
what gender each sample should be based on the gender specific SNPs included on the 
genotype chip. This can then be checked against their actual gender to make sure the 
check was accurate. All samples identified as their actual gender except sample 24. For 
that sample, it came back as no identified gender. Since this does not actually indicate a 
crossover of samples, merely an error in the chip read, and the sample size is fairly small, 
sample 24 was not removed from the sample set. Second, using command 15, a list of 
any SNPs with greater than 5% missing genotypes amongst the samples was created. This 
list was then transferred to a text file to be able to remove those SNPs using the same 
“exclude” command as in command 10. There were ~50,000 SNPs removed due to this 
error from the genotyping chip (Table 4). Finally, command 16 was used, which tests the 
data using the Hardy-Weinberg equilibrium (HW). This test looks at SNPs from a 
perspective of high frequency due to close relationship between participants. It is 
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common for high HW p-values when there is inbreeding and lack of diversity in a 
population (Wiggington, 2005). Since we are examining a specific Hispanic population 
for genetic biomarkers, it was important to make sure there wasn’t any bias introduced in 
the analysis if they all were closely related. There were about 2,800 SNPs removed due to 
failing the HW test (Table 4). This left a little over 132,000 SNPs per sample for data 
analysis. 
3.3.5 Association Analysis 
Using command 17, the association analysis was completed on the data. This 
produced a list of every SNP and its associated p-value. The lower the p-value the more 
statistically significant the SNP is for the tested trait, which in this case is susceptibility to 
Type 2 Diabetes. In order to handle and analyze the data, it was converted to a form that 
can be used in Haplowview, which is a bioinformatics software that allows sorting and 
processing of genetic data. In Haplowview the association results were sorted by p-value 
from low to high and the data with the lowest 10% of p-values was selected for further 
processing. A Manhattan plot was created in Haplowview to visualize the significance in 
the variation (Fig 8) and this was used to assist in reducing the top SNPs to 10% of the 
lowest p-values due to the lessening of the SNP density at that point in the plot (red line). 
These SNPs were compared to the reference data associated with the Cardio-metabochip 
to determine which of these top 10% SNPs were associated with Type 2 Diabetes. During 
this process, the nearest gene for each of these top SNPs was also determined by using 
the dbSNP database from NCBI. This database contains all genetic variation for humans 
along with a variety of information known about each SNP including gene and type of 
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mutation present. The results of this analysis produced 26 SNPs associated with Type 2 
Diabetes (Table 5). The rs# is a standard code used to identify SNPs. The table shows the 
name of each SNP, the chromosome where it is located, the two alleles with the SNP 
allele listed second, the nearest gene, and p-value. All SNPs have a significant p-value 
and are fine-mapping SNPs from the chip. Therefore, although these SNPs are located in 
regions that have been associated or suspected for Type 2 Diabetes susceptibility, none of 
the 26 SNPs have been directly linked to Type 2 Diabetes before. Thus we have 
identified new potential biomarkers for Type 2 Diabetes susceptibility in a Hispanic 
population. 
 
Figure 8. Manhattan Plot of Genotyping Data 
 
A Manhattan plot shows all the SNPs sorted by chromosome location after association 
analysis. The blue line is the minimum p-value for statistical significance and the red line 
is an arbitrary value chosen based on the lessening of SNP density. All SNPs above the 
red line were examined further for Type 2 Diabetes related SNPs.
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Table 5. Top 26 SNPs 
 
After analysis there were 26 SNPs associated with Type 2 Diabetes in the Hispanic 
population studied. The rs# is the common code used for identifying SNPs. The two 
possible alleles are listed for each SNP as well as the nearest gene and p-value from the 
association analysis. All SNPs are located in introns or near the listed gene. Several SNPs 
are not close to a gene and therefore they are listed as unknown. 
# SNP ID Chr Alleles 
1/2 
Nearest 
Gene 
p-value 
1 rs17497477 17 A/C TBC1D3P1-DHX40P1 1.39E-04 
2 rs2185756 10 C/A EIF2S2P3 2.94E-04 
3 rs4383556 3 A/C IGF2BP2 3.14E-04 
4 rs17293846 3 C/T IGF2BP2 3.14E-04 
5 rs17826758 3 G/A IGF2BP2 3.14E-04 
6 rs73175565 3 C/T IGF2BP2 3.14E-04 
7 rs73175555 3 G/T IGF2BP2 6.55E-04 
8 rs191990500 3 C/A IGF2BP2 9.50E-04 
9 rs9834931 3 A/C IGF2BP2 1.09E-03 
10 rs7646419 3 A/G IGF2BP2 1.09E-03 
11 rs6780808 3 A/G IGF2BP2 1.09E-03 
12 rs6781019 3 T/C IGF2BP2 1.09E-03 
13 rs6457742 6 T/C unknown 1.09E-03 
14 rs2891226 14 T/C NPAS3 2.14E-03 
15 rs1320195 10 T/A CDC123 2.70E-03 
16 rs10875142 1 C/T unknown 3.19E-03 
17 rs12213132 6 G/A CDKAL1 3.19E-03 
18 rs7005401 8 A/G CRISPLD1 3.19E-03 
19 rs9848681 3 C/T IGF2BP2 3.27E-03 
20 rs2682919 15 C/T unknown 3.27E-03 
21 rs6791275 3 T/C IGF2BP2 4.34E-03 
22 rs289107 15 C/A FLJ38723 4.43E-03 
23 rs7300366 12 A/G IFFO1 4.59E-03 
24 rs7697417 4 A/G BEND4 5.83E-03 
25 rs72657613 6 G/A CDKAL1 5.83E-03 
26 rs188617336 6 T/C CDKAL1 5.83E-03 
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3.3.6 Comparison to Reference Populations 
Since this study was a pilot study with a smaller sample size, secondary analysis 
was completed to attempt to validate the top 26 SNPs identified through the association 
analysis. This was done by comparing the allelic frequencies of the identified SNPs to the 
reference allelic frequencies of related populations. It is known that Mexican Hispanic 
populations have genetic similarity between Native American populations and European 
populations due to the colonization of the Americas by Europeans (Parra, 2011). 
Therefore two populations were chosen to be similar in genetic background to our 
population: another Mexican population and a central European population. These sets of 
data were obtained from the HapMap project (International HapMap Consortium, 2010), 
which is a consortium developed to identify all genetic variation in all populations across 
the Earth. We also examined a population that should be genetically different from our 
Hispanic population, which was a Chinese and Japanese population group. All reference 
populations were assumed to be healthy. Using equation 3, the percent difference 
between these reference populations and the case group of our Hispanic population was 
calculated (Table 6). The average %Diff was calculated and used to identify those SNPs 
that were above the average and therefore significantly different between the two groups. 
There were five in each of the two similar populations that had a %Diff above the 
average with many more right around the average. This supports the fact that there is a 
difference in allelic frequency between other healthy populations and our Type 2 
Diabetes group. Further, the %Diff for the Chinese and Japanese group was very 
different, many of which had values that were more than double the %Diff with related 
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populations. This is expected since this population is very different from our study 
population. Genetic variation frequency is expected to be different in disease, but since 
SNPs usually only occur in small percentages, a %Diff that is extremely large would 
indicate a difference in genetic background rather than a disease biomarker. This is why 
it is important to complete quality control measures. All in all, the results of this 
comparison supports that our Hispanic population is closely related to Mexican and 
European populations and that there is some significant variation between the two, which 
is likely an indicator that these SNPs can be used as biomarkers for Type 2 Diabetes in 
Hispanic populations.
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Table 6. Comparison to Reference Populations 
SNP ID Case* MXL % Diff CEU % Diff CHB-JPT 
% 
Diff 
rs17497477 0.444 0.2891 53.6 0.2235 98.7 0.125 255.2 
rs2185756 0.667 0.6250 6.72 0.5588 19.4 0.342 95.0 
rs4383556 0.694 0.8438 17.8 0.7941 12.6 N/A -- 
rs17293846 0.694 0.8438 17.8 0.7824 11.3 0.975 28.8 
rs191990500 0.333 N/A --† N/A -- N/A -- 
rs17826758 0.694 0.8438 17.8 0.7824 11.3 0.975 28.8 
rs73175565 0.694 0.8438 17.8 0.7882 12.0 N/A -- 
rs73175555 0.694 0.8359 17.0 0.7706 9.94 0.958 27.5 
rs9834931 0.583 0.7109 18.0 0.5941 1.87 0.692 15.7 
rs7646419 0.583 0.7109 18.0 0.5882 0.88 0.692 15.7 
rs6780808 0.583 0.6953 16.2 0.5941 1.87 0.667 12.6 
rs6781019 0.583 0.7109 18.0 0.5941 1.87 0.692 15.71 
rs6457742 0.583 0.6016 3.09 0.5235 11.4 0.783 25.52 
rs2891226 0.528 0.6563 19.5 0.5941 11.1 0.883 40.23 
rs1320195 0.500 0.8125 38.5 0.6882 27.3 N/A -- 
rs10875142 0.722 0.8203 12.0 0.6588 9.59 0.925 21.9 
rs12213132 0.722 0.8438 14.4 0.6647 8.62 0.958 24.6 
rs7005401 0.722 0.8984 19.6 0.8412 14.2 0.883 18.2 
rs9848681 0.583 0.6875 15.2 0.5529 5.44 0.667 12.6 
rs2682919 0.583 0.6797 14.2 0.5588 4.33 0.475 22.7 
rs6791275 0.556 0.6797 18.2 0.5765 3.56 0.667 16.6 
rs289107 0.389 0.5859 33.6 0.7188 45.9 0.658 40.9 
rs7300366 0.639 0.7578 15.7 0.7412 13.8 0.733 12.8 
rs7697417 0.694 0.7031 1.29 0.5647 22.9 0.633 9.6 
rs72657613 0.694 N/A -- N/A -- N/A -- 
rs188617336 0.694 N/A -- N/A -- N/A -- 
Ave ± SD  18.4 ± 11.0 15.6 ± 20.7 37.1 ± 54.6 
The %Diff is the calculated percent difference between the allelic frequency of the case 
group from the study population and the reference population. All reference populations 
came from HapMap Consortium data. MXL is Mexican from Los Angeles, CA, CEU is 
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Central European from Utah, and CHB/JPT is Han Chinese from Beijing, China plus 
Japanese from Tokyo, Japan. The first two are for comparison with similar population 
groups and the third is for contrasting with a very different population group. 
 
3.3.7 PCA 
Finally, to further validate our top SNPS, the 26 SNPs were analyzed using PCA. 
Since the dataset was small, XLstat was able to be used for PCA analysis, which 
automatically graphs the results. Even with both a small number of samples and a small 
number of SNPs, the case and control group clearly separate (Fig 9A) between case 
(blue) and control (red). This supports that there is a genetic factor in the susceptibility 
for Type 2 Diabetes in a Hispanic population and that factor is strong enough to separate 
the sample groups even with a small set of variables. Further, a coordination plot of the 
SNPs (Fig 9B) shows that they separate into three groups. This could mean that there are 
subclasses of variation for Type 2 Diabetes as has been suggested in the literature (Murea 
et al., 2012). For example, the three SNPs that separate out on the bottom left of the plot 
are rs17497477, rs289107, and rs2185756. The first two are the top two SNPs and the last 
is a SNP that had significantly different allelic frequency from all the reference 
populations. This further supports the idea that the top SNPs for Type 2 Diabetes could 
be put into subcategories. However, further work needs to be done to confirm this.
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Figure 9. PCA of Hispanic Population Data 
A. 
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A. PCA Biplot of the top 26 SNPs. Case is blue and control is red. Even with a small 
sample size and 26 SNPs, the case and control separate into two groups. B. Coordination 
plot with top 26 SNPs. The SNPs separate into three groups. The bottom left group 
coincides well with the comparison to reference population data. 
 
 3.4 Conclusion 
After completing the pilot study for Type 2 Diabetes, there were 26 SNPs that 
were statistically significant for disease susceptibility in our Hispanic study population. 
This supports the hypothesis that there are genetic factors that increase susceptibility for 
Type 2 Diabetes in Hispanics. This was further confirmed in that 7 of the top SNPs also 
showed difference above the average in allelic frequency compared to similarly related 
reference populations. Further, the small number of samples and SNPs were able to 
separate case and control on a PCA biplot. In addition, the number of SNPs that were 
statistically significant would support the multifactorial nature of Type 2 Diabetes in that 
it is a combination of many SNPs that adds up to disease. The coordination plot might 
suggest that there are also subcategories to the set of SNPs and therefore in Type 2 
Diabetes, but more would need to be done to conclude this. In future, using the pilot 
study data as preliminary results, the research can be expanded to include a larger number 
of participants to validate the 26 SNPs and possibly identify others that are too rare to be 
detected in the smaller sample set. 
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CHAPTER IV 
OPTIMIZATION OF A WHOLE CELL BETA-GALACTOSIDASE ASSAY IN 
GRAM-POSITIVE BACTERIA 
 
4.1 Introduction 
 
4.1.1 Identifying the Role the Gut Microbes Play in Susceptibility 
In order to understand how the gut microbiome affects human health and disease, 
new methods need to be developed to identify the activity the microbes have in the gut 
environment including how they interact with food and medicine as well as how they live 
in symbiosis with the host. If patterns of activity can be detected, then perhaps how the 
gut microbiome influences the development of Type 2 Diabetes and other metabolic 
disorders can be unraveled. In order to study the patterns of activity, models of the gut 
microbes need to be built and tested to simplify the creation and optimization of new 
methods of detection.  
4.1.2 Modelling the Gut Microbiome 
Since most gut microbes cannot be cultured, the easiest option for model systems 
is probiotic bacteria. Probiotics are microbes that produce health benefits for humans. 
They can be cultured and are common in different food products like yoghurt (Tamang et 
al., 2016) and many of them are also native to the gut, supporting their compatibility in 
food products. It is because of these properties that probiotics would make an ideal 
choice for developing a model for testing gut microbes. At the same time, a large 
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proportion of probiotic bacteria are gram-positive. This means they have a thick 
peptidoglycan layer around their cell wall. Because of this, there is a limit to what 
substrates can be used and gram-positive cells may be difficult to work with when 
performing assays (Delcour et al., 1999).Therefore, starting with a simple model will 
help to understand how new methods will work on probiotic, and thus gut, microbes. To 
begin with, the simplest model is a single pure culture of probiotic bacteria. The strain 
chosen was Lactobacillus helveticus (ATCC 15009). It is a gram-positive bacteria that is 
commonly found in certain cheese cultures and has also been detected in the gut 
(Taverniti & Guglielmetti, 2012). It is from the Lactobacillus genus, which is made up of 
many other probiotics and it is one of the better studied genus’ of bacteria (Kant et al., 
2010). Therefore studying L. helveticus will provide a good foundation for developing 
methods of microbial activity detection. 
4.1.3 Microbe Activity 
With three potential targets for activity detection, deciding which is the most 
appropriate for the goal is the first step to begin designing new methods. Since this is the 
first thing that needs to be answered, a known substance was chosen to measure and 
compare between the three targets. Beta-galactosidase is an enzyme that is part of the 
metabolism of many organisms. Its main reaction is to cleave lactose into glucose and 
galactose so it can be used as an energy source. The enzyme is well-studied and has been 
used extensively as a reporter molecule with a variety of colorimetric and fluorescent 
substrate options (Alam & Cook, 1990; Miranda et al. 2010). Further, the lac operon, the 
gene that codes for beta-galactosidase, is well understood and is naturally repressed in 
57  
bacterial systems. The repressor is turned off by the presence of lactose and thus using a 
lactose based media to grow the cells could activate the target of detection and simulate 
an activity scenario in the gut (Citti et al., 1965; Fortina et al., 2003). At the same time, 
using beta-galactosidase allows the detection of all three possible activity targets for gut 
microbes. That is, the enzyme, and thus the metabolites it produces, as well as the mRNA 
for the gene are known and therefore can be studied to help determine which target would 
be ideal for tracking the activity of gut microbes.  
Since there are already designed substrates for detecting enzymatic activity of 
beta-galactosidase, the protein/metabolite target was chosen as the first part of the study. 
There are several options for substrates, but a fluorescent one was used due to the 
increased sensitivity possible with fluorescent measurements over colorimetric 
measurements. The substrate is 4-Methylumbelliferyl β-D-galactopyranoside (MUG) and 
the structure and reaction with beta-galactosidase is shown in Figure 10. MUG has a 
galactose moiety, which the enzyme recognizes and binds in its active site. The enzyme 
then cleaves the bond between the saccharide and the fluorophore to release them and 
enhance fluorescence to a detectable level (Grange & Clark, 1977). Since MUG is a small 
molecule with a similar structure to lactose, it should not be hindered from passing into 
the cell and being acted on by the enzyme. The goal then is to turn on the production of 
the enzyme and measure the activity using MUG. If an assay can be optimized to detect 
relative levels of enzyme activity, then the viability of the assay as a detector for activity 
can be determined and compared to the measurement of the mRNA for the beta-
galactosidase gene for bacterial activity.
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Figure 10. Reaction of MUG with Beta-galactosidase Enzyme 
 
 
 
 
 
 
 
 
Structure of MUG substrate and the reaction with beta-galactosidase. MUG has a similar 
structure to lactose with a galactose moiety (left half of substrate) with the fluorescent 
moiety in place of glucose. The enzyme cleaves MUG to produce 4-MU, a fluorescent 
product, which can be detected, indicating enzyme activity. 
 
 
4.2 Method 
4.2.1 Bacteria Stock 
Lactobacillus helveticus (ATCC 15009) was purchased from the American Type 
Culture Collection (ATCC) and the culture was started in 5 mL of deMan, Rogosa, and 
Sharpe (MRS) media using the provided protocol. Growth was at 37oC with 5% CO2 for 
24 hours. After this initial growth, 10 µL of L. helveticus was inoculated into a fresh 5 
mL tube of MRS media and grown until the late log phase based on optical density (OD) 
at 600 nm. Then the culture was decanted into a 15 mL centrifuge tube and centrifuged at 
3000 x g for 15 min at 4oC. The supernatant was removed and the cells were then 
resuspended in an equal volume of fresh MRS media containing 20% (w/v) sterile 
glycerol. The stock was aliquoted into cryogenic tubes and stored at -80oC.  
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4.2.2 Growth Curve 
A growth curve was plotted to determine how long it would take for the bacteria 
to reach the log phase of growth. L. helveticus was grown in MRS media for 48 hours 
with measurements of OD at 600 nm approximately every 2 hours. Further, to see how 
the cells respond, a growth curve was also done for L. helveticus in MRS media that 
contained lactose as the only sugar source (LMRS) using the same parameters. Each 
growth curve used a 10 µL inoculation in a 5 mL volume of media in duplicate and OD 
was tested directly in the culture tube in a Genesis10 UV/Vis Scanning Spectrometer 
(ThermoSpectronic). The average OD for each time point was calculated and plotted 
against the time in hours. 
4.2.3 Initial Assay Conditions 
The initial assay was based on a gram-negative method from Vidal-Aroca et al. L. 
helveticus was grown in 5 mL of MRS media at 37oC with 5% CO2 to the late log phase 
to bring the cells out of a freezer state. Then 10 µL was inoculated in 5 mL LMRS and 
grown overnight in the same conditions. The OD at 600 nm was measured and then cell 
aliquots of 20 µL were dispensed into a 96-well plate and 80 µL of z-buffer was added 
followed by 25 µL of 1 mg/mL MUG in DMSO. The reaction mixture was incubated for 
15 mins and then the reaction was stopped with 30 µL of 1 M Na2CO3. The fluorescent 
product was measured on a POLARstar OPTIMA plate reader (BMG labtech) with 
excitation at 365 nm and emission at 445 nm. Z-buffer was made based on the procedure 
from Miller. After it was made, it was filtered through a 0.2 micron filter to remove 
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impurities and then stored at 4oC until use. A fresh aliquot of z-buffer was prepared for 
each assay by adding 14 µL of β-mercaptoethanol per 5 mL of z-buffer prior to use.  
4.2.4 Testing for Background Noise 
L. helveticus was grown and activated as before. To test for background caused by 
the cells, they were washed once in either 1X PBS buffer, z-buffer, or fresh LMRS 
media. Further, the two buffers and the LMRS media were added in place of cells in the 
MUG controls to look for any interaction. The assay was completed with the initial 
parameters and the results compared.  
4.2.5 MUG Concentration 
Different MUG concentrations were tested to optimize the signal-to-noise ratio. A 
serial dilution of MUG was created in DMSO from 5 mg/mL to 0.002 mg/mL and tested 
for beta-galactosidase activity. Controls were also made to include each MUG 
concentration without cells. The fluorescent signal was used to calculate the signal-to-
noise ratio and based on that, an optimum MUG concentration was determined. 
4.2.6 Activation 
In order to test how activation works and how long is necessary, L. helveticus was 
grown in three tubes and tested at 1, 2, and 4 hours. For each time point, 4.5 mL of cells 
were centrifuged for 15 min at 3000 x g and 4oC and then resuspended in 500µL of 
LMRS and serially diluted until a minimum OD was reached. All samples were tested for 
beta-galactosidase activity. Using the serial dilutions, a standard curve was created of OD 
vs. fluorescent signal in order to normalize the fluorescent signal at each time point to be 
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comparable for beta-galactosidase activity rather than just cellular growth. The results 
were then compared to determine activation time.  
4.2.7 Linear Dynamic Range 
Using the newly optimized parameters, L. helveticus was activated for 4 hours, 
and then 15 mL of culture was collected and centrifuged at 3000 x g for 15 min at 4oC. 
The supernatant was decanted then the cells resuspended in 400 µL of z-buffer. The cell 
concentrate was serially diluted in 1:2 ratios with z-buffer and then each dilution was 
aliquoted into a 96 well plate. The cells were incubated with MUG for 15 min and then 
the reaction stopped as before. The dilution level was plotted against the fluorescent 
signal to determine the linear dynamic range of the assay for L. helveticus. 
4.2.8 Reproducibility of the Assay 
The reproducibility of the assay was tested on a different strain of gram-positive 
bacteria: Lactobacillus reuteri (ATCC 53609). Bacteria stock and a growth curve were 
created for L. reuteri using the same method as before. L. reuteri was then processed 
through the same assay parameters as for L. helveticus to create a linear dynamic range. 
The results were plotted and compared to determine if the assay was reproducible on this 
strain.  
4.3 Results/Discussion 
4.3.1 Initial Growth of L. helveticus 
The pure strain of L. helveticus was purchased from ATCC and successfully 
started using the provided instructions. The stock was created through a single transfer 
from the purchased strain culture. This was done to avoid contamination and to ensure 
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the stock was as close to the purchased culture as possible. Further, each assay was 
started from stock so that there was consistency for each experiment and thus 
comparability. 
The growth curve was created for both MRS and LMRS media (Fig 11).  L. 
helveticus reached the beginning of the log phase at around 10 hours and ended around 
30 hours with the 10 µL inoculation volume. Further, the bacteria responded nearly 
identically to both types of media with just a small variation at the end phase of growth. 
This indicates that this strain of bacteria can use glucose and lactose with equal efficiency 
and therefore the growth is not drastically altered by introducing the different sugar 
source. Further, this indicates that L. helveticus can grow on lactose and thus it has an 
active beta-galactosidase enzyme. 
 
Figure 11. L. helveticus Growth Curve 
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A growth curve was created to understand how L. helveticus (LH) responds to the two 
different sugar sources in the media. Blue is MRS media with glucose and Red is LMRS 
media with lactose. Cells were grown over a 48 hour period at 37oC with 5% CO2.  
4.3.2 Results of Initial Assay 
The initial assay conditions were based on a gram-negative assay in whole cells. 
First, L. helveticus is started from stock in MRS media to bring the cells up to active 
growth from the freezer. Then they are inoculated into LMRS media to activate the beta-
galactosidase enzyme. The assay uses a fluorescent substrate to increase sensitivity of the 
assay due to the possibility of low signal caused by working with whole cells. Before 
going through the process of optimization, the gram-negative assay was tested on the 
gram-positive bacteria to see if signal could be achieved. Using the parameters from 
Vidal-Aroca et al., L. helveticus was tested for beta-galactosidase activity (Fig 12). The 
blank is z-buffer and the two controls are for MUG background noise, which included 
MUG with media in place of cells, and cell background noise, which included L. 
helveticus with DMSO in place of MUG. The buffer by itself has minimal noise, but both 
controls are at essentially the same fluorescent signal as the reaction sample. Thus signal 
above the noise was not achieved using the initial parameters and optimization was 
necessary. Specifically, optimization was needed to address the large background noise 
of the controls as well as to examine other aspects of the assay to improve the reaction 
signal and the assay time.
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Figure 12. Initial Assay Results 
 
The initial assay parameters were tested and the fluorescent levels compared between the 
reaction sample and the controls. Blank is z-buffer, MUG control is everything but cells, 
and L. helveticus control is everything but MUG. 
 
 
4.3.3 Background Noise 
Due to the high background noise produced by the initial assay, several different 
aspects of the assay were tested. First, to examine if the cells or the media were 
producing noise, the cells were washed in once z-buffer, PBS buffer, or fresh LMRS 
media and then tested for fluorescence without MUG to see if the background noise was  
reduced. PBS buffer was chosen as a gentle buffer that works well with the majority of 
cell cultures without damaging them and z-buffer was used since it is the assay buffer so 
it is compatible with the rest of the assay. By also washing with fresh media, it could be 
determined if the cells were producing a compound that fluoresces at the same 
wavelengths as the substrate or if it was the media producing the noise. As can be seen in 
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Figure 13, washing just once with either buffer eliminates the noise in the cell controls. 
However, the control that was washed with media maintains a higher level of noise. 
Therefore the media produces background noise at the detection wavelength and washing 
with buffer removes the media and the noise. Both buffers worked equally well and thus 
the z-buffer was used in future to reduce the number of solutions needed for the assay. 
Second, the MUG was tested at 1 mg/mL with either of the buffers or fresh media added 
in place of the cells to confirm that the MUG gave high background noise and to see if 
there were any negative interactions between the buffers and the substrate. The results 
confirmed that the MUG is giving large background noise at the concentration used. The 
buffer did not have an effect on the substrate and the media noise is confirmed in the 
MUG controls as the signal from the MUG with media is higher than the MUG with 
either buffer. Thus further work needed to be done to address the MUG concentration.  
 
Figure 13. Sources of Background Noise 
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The MUG substrate and the media were tested for background noise in the assay. All 
samples listed are controls. Blank is z-buffer, the three MUG controls have LMRS media, 
PBS buffer, or z-buffer respectively in place of cells. The washed cells have DMSO in 
place of MUG and were washed once in either PBS buffer, z-buffer, or fresh LMRS 
media. 
 
 
4.3.4 MUG Concentration 
It was verified that the MUG at 1 mg/mL was producing too much background 
noise. Therefore, a serial dilution was created to assess what concentration would be best 
for the assay with gram-positive bacteria. The higher concentration was to asses if more 
MUG was needed to induce the cells to take it in and allow the beta-galactosidase to act 
on the substrate. The dilutions went down about three orders of magnitude to test a wide 
range of concentrations. The controls are MUG with z-buffer in place of cells and the 
reaction mixture has activated cells with the MUG (Fig 14A). The higher MUG 
concentrations produced more signal with the cells while the lowest concentrations 
produced neither signal nor noise. The lowest concentrations were either below the 
detectable level of fluorescence or not high enough to encourage diffusion into the cell 
and therefore could not react with the enzyme. To understand which of the higher 
concentrations was best, the signal-to-noise ratio was calculated and plotted against the 
concentration (Fig 14B). Based on the signal-to-noise ratio, 0.2 mg/mL was the best 
MUG concentration as the curve peaks at that concentration. The concentrations above 
this appear to have higher signal from the reaction, but the noise is also increased 
proportionally and therefore the ratio decreases. Thus the future assays used a MUG 
concentration of 0.2 mg/mL. 
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Figure 14. Changing MUG Concentration to Increase Signal-to-noise Ratio 
 A. 
 
B. 
 
A. A serial dilution of MUG was made from 5 mg/mL to 0.002 mg/mL in DMSO then 
each concentration tested on activated L. helveticus with their respective controls. B. The 
signal-to-noise ratio of the MUG concentrations was calculated and then plotted against 
concentration of MUG. The best signal-to-noise ratio is achieved at 0.2 mg/mL of MUG.
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4.3.5 Activation of Beta-Galactosidase 
In addition to background noise, the time the assay took was a negative aspect to 
the original parameters. Since the cells are grown in MRS first and then activated 
overnight in LMRS, the assay takes several days to complete. Thus it would be ideal to 
have a shorter activation time to keep the assay to one day. We hypothesized that since 
the beta-galactosidase gene is off when the cells have their normal sugar source, the 
activation with lactose would be exponential. That is, cell growth will increase the 
amount of beta-galactosidase enzyme and over time the cells will also contain more 
enzyme. Specifically, the lac operon is repressed when lactose is not present (Fig 15A). 
When cells are inoculated into LMRS media, the lactose will turn on the gene and start 
producing beta-galactosidase enzyme. The form of the lac operon for L. helveticus is 
different than the normal lacz type gene. It produces a heterodimeric enzyme that has the 
same activity, but different structure and stability. This is part of the reason for choosing 
a whole-cell assay and testing the activation of the enzyme. Figure 15B shows the 
hypothesized mode for exponential increase of beta-galactosidase enzyme. After only 1 
hour of growth there will be cell replication, but since it is early in the growth period, 
only a few beta-galactosidase enzymes will have been made. After 4 hours, enough time 
has passed to produce a significant amount of enzyme per cell as well as more cell 
growth. Thus the increase in signal after the start of activation will be exponential.  
To test this, the cells were activated and tested at 1, 2, and 4 hours. As would be 
expected, the amount of signal increases as the activation time increases (Fig 16A). In 
order to determine if this increase is due to just cell growth, and thus the amount of 
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enzyme remains constant, or if there is an exponential increase, the 1 and 2 hour time 
points were normalized to the same OD as the 4 hour time point (Fig 16B). With 
normalization the signal increases exponentially and thus our hypothesis was correct. 
Further, after only 4 hours there is a strong enough signal to be detectable and therefore 
activation overnight is not necessary. Further, since cells are started in MRS, more can be 
used to inoculate in the LMRS to achieve the log phase in a shorter time as was done 
here. By doing this, the activation time is reduced and as a consequence the whole assay 
time is reduced and can be accomplished in one day. 
 
Figure 15. Beta-galactosidase Activation  
 
 A.  
 
 
 
 B. 
 
 
 
 
 
 
 
A. The LacL/LacM form of lac operon found in L. helveticus. The gene produces the 
beta-galactosidase enzyme, but gene expression is repressed unless in the presence of D-
1 hour 
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LacL LacM LacR 
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lactose because the repressor is located upstream (LacR). The enzyme is a heterodimer 
with the two genes overlapping each other (LacL & LacM). Other side components of the 
gene are located on either end of the dashed lines, but are irrelevant to the study. B. 
Hypothesized mechanism for activation over time. Red spots represent beta-galactosidase 
enzyme and the brown boxes represent cells. Figure depicts how exponential increase of 
beta-galactosidase production might occur.  
  
Figure 16. Results of Activation Study 
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A. L. helveticus was tested at 1, 2, and 4 hours for activity. The bars represent the OD at 
600 nm and the line represents the fluorescent signal. B. The three time points normalized 
to the 4 hour OD. The line continues to increase even when the OD is the same indicating 
beta-galactosidase production is exponential. Error bars are present, but not large enough 
to be visible.  
 
 
4.3.6 Linear Dynamic Range 
After optimizing the assay, the linear dynamic range needed to be determined. 
This shows the range of cell concentration that produces a detectable signal. The cells 
were concentrated to the maximum OD and serially diluted to determine this range. The 
plot is of fluorescent signal versus dilution level (Fig 17). It shows that the linear 
dynamic range is a little over two orders of magnitude. Thus the assay is sensitive over a 
large range of cellular concentrations. This validates the effectiveness of the optimization 
parameters and   indicates that the assay can be used with a variety of cellular 
concentrations. This is useful since cellular growth is not always consistent and the assay 
can still be completed even if the cellular concentration is higher or lower than expected 
rather than lose a day of work to restart the cell growth and activation. 
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Figure 17. Linear Dynamic Range of Assay for L. helveticus 
 
L. helveticus was concentrated to a maximum OD and then serially diluted to the lowest 
possible OD. After the assay, the resulting fluorescence was plotted against dilution level 
to determine linear dynamic range. R2 is shown to depict how well the trend line fits the 
data. Error bars are present, but too small to be seen. 
 
 
4.3.7 Reproducibility of the Assay in Another Gram-Positive Bacterial Strain 
Since the goal of this assay was to be optimized for gram-positive bacteria, the 
new assay parameters were tested on a different strain to see if the results were 
reproducible. L. reuteri was purchased from ATCC and stock was made as before. L. 
reuteri is closely related to L. helveticus and is also a probiotic as well as a gut microbe. 
Thus is it expected to have an active beta-galactosidase enzyme. On the other hand, it is a 
different strain of bacteria and thus it likely produces different secondary metabolites has 
slightly different activity. To determine if L. reuteri is compatible with the LMRS media 
and thus has a robust beta-galactosidase enzyme, a growth curve was made using the 
same method as for L. helveticus to examine the growth rate (Fig 18). The growth curve 
shows that L. reuteri grows well in both types of media, with just a slight difference in 
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the log phase between MRS and LMRS. However the cells reach the levelling off of 
growth stage at the same time and reach the same level of OD and therefore L. reuteri can 
grow well in the LMRS media. Further, it grows faster than L. helveticus confirming that 
is has a slightly different metabolism despite being closely related. Knowing this, using 
L. reuteri will help determine if the assay can be used on a beta-galactosidase enzyme in 
gram-positive cells with different properties and therefore the assay is applicable to 
different strains of gram-positive bacteria. 
 
Figure 18. Growth Curve for L. reuteri 
 
Growth curve completed using same method as with previous strain of bacteria. Blue is 
with MRS media and red is with LMRS media. The growth curve covered a period of 48 
hours grown at 37oC with 5% CO2.  
 
Since L. reuteri was confirmed to grow well in the presence of D-lactose, it was 
subject to the optimized beta-galactosidase assay parameters. The linear dynamic range 
was tested and plotted using the same conditions as for L. helveticus (Fig 19). For L. 
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reuteri the linear dynamic range is three orders of magnitude. Therefore, the assay is 
reproducible in a different strain of gram-positive bacteria. Further, the linear dynamic 
range is improved for this strain. Thus supports the idea that different strains will 
responds slightly differently to the assay due to the difference in their metabolism, but the 
assay is applicable nonetheless.  
 
Figure 19. Linear Dynamic Range for L. reuteri 
 
To confirm the repeatability of the assay on a different strain of bacteria, a linear dynamic 
range was determined for L. reuteri using the same assay parameters as before. Linear 
dynamic range increased with this strain of bacteria and thus the assay can be reproduced 
in other gram-positive bacteria. Error bars are present, but too small to be seen.  
 
 
4.3.8 Conclusion 
 An activity assay for beta-galactosidase enzyme was completed in gram-positive 
bacteria. The initial results proved that optimization was necessary to adapt a gram-
negative method to work for gram-positive bacteria due to the difference in cellular 
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structure and possibly interaction between the substrate and the cells. Optimization was 
successful with a reasonable linear dynamic range and validation with a different strain of 
gram-positive bacteria. With the enzyme assay completed, the next steps of the 
microbiome model can be developed and optimized. This will include examining the 
mRNA of the beta-galactosidase gene and comparing it to the enzyme activity to 
determine which activity test is ideal. Further, a mixed microbe model will be tested for 
activity to mimic a simple gut environment and microbial interactions. Ultimately the 
goal will be to develop a method of detecting activity, that is which microbes are actively 
involved in human health and disease, and applying this method to gut microbe samples 
for the detection of patterns in activity that link to how the gut microbes increase 
susceptibility for Type 2 Diabetes and other diseases. 
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CHAPTER V 
CONCLUSIONS 
 
 Overall, by using a newly developed microarray chip, the research in this 
dissertation has completed a pilot study on the genetic biomarkers for Type 2 Diabetes 
among Hispanic adults. The genetic biomarkers can be used to define the hosts in future 
studies on the relationships between the hosts and gut microbiome and other related 
clinical studies. Using statistics tools, the pilot study successfully identified 26 SNPs 
associated with Type 2 Diabetes in a Hispanic population. These results were supported 
by secondary analysis with reference populations and PCA. The PCA results indicated 
that there is a genetic basis for Type 2 Diabetes based on the clear separation between 
individuals with Type 2 Diabetes and individuals without. This was seen in both the 
reference Geneva data set as well as the Hispanic study population. In both data sets, 
there were indications that multiple SNPs were required to the development of diabetes 
as seen by the number of SNPs needed to maintain separation in the PCA biplots as well 
as the number of SNPs isolated in the Hispanic study. Furthermore, Type 2 Diabetes 
SNPs were detected in the Hispanic population and this suggests that there is a genetic 
factor that increases the susceptibility to diabetes. Future work will increase the sample 
size to validate the SNPs and possibly identify more SNPs as well as the mode of action 
these genetic variants have in the host. 
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The need for optimizing the beta-galactosidase assay indicated that gram-positive 
bacteria do behave differently from gram-negative bacteria, thus different assay 
conditions were needed to maintain the detectability of a specific activity. The assay time 
was also reduced to one day to improve the protocol and make it quicker and easier for 
future comparison of different activities. The beta-galactosidase assay is considered to be 
equivalent to measuring a specific protein or metabolite (4-MU). Now that the assay is 
developed and validated, the next steps will include measuring the mRNA of beta-
galactosidase, and building a more complex model with mixed microbes and detect their 
corresponding activities. Ultimately, the goal is to develop a method for monitoring the 
activity of entire gut microbes and further our understanding on the relationships between 
the host and gut microbes on the development and/or treatment of Type 2 Diabetes.
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APPENDIX A 
PLINK COMMANDS 
 
 
I. Chapter 2 
(Command 1) ./plink --bfile Genevadata --keep Sample100.txt --make-bed --out 
first100data 
(Command 2) ./plink --bfile first100data --indep-pairwise 1000 50 0.05 --exclude range 
exclusion_regions.txt 
(Command 3) ./plink --bfile first100data --extract plink.prune.in --make-bed --out 
data_pruned 
(Command 4) ./plink --bfile first100data --assoc --out first100assoc 
(Command 5) ./plink --bfile first100data --extract pvalue05.txt --make-bed --out 
05Sample100 
(Command 6) ./plink --bfile data_pruned --pheno First100NoPheno.txt --make-bed --out 
datapruned_nopheno 
(Command 7) ./plink --bfile 05Sample100 --pheno First100NoPheno.txt --make-bed --out 
First100nopheno
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(Command 8) ./flashpca_x86_64 --bfile datapruned_nopheno 
(Command 9) ./flashpca_x86-64 --bfile First100nopheno 
II. Chapter 3 
(Command 10) ./plink --file mydata --exclude snplist.txt --make-bed --out mydata2 
(Command 11) ./plink --bfile mydata2 --pheno Pheno.txt --make-bed --out mydata3 
(Command 12) ./plink --bfile mydata3 --update-sex Gender.txt --make-bed --out mydata4 
(Command 13) ./plink --bfile mydata4 --update-ids Recoded.txt --make-bed --out t2ddata  
(Command 14) ./plink --bfile t2ddata --sex-check 
(Command 15) ./plink --bfile t2ddata --missing --out missingstats 
(Command 16) ./plink --bfile t2ddata --hardy --out HWstats 
(Command 17) ./plink --bfile t2ddata --assoc --out assoc1  
(Command 18) ./plink --bfile t2ddata --recodeHV --out haplowviewdata --gplink
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APPENDIX B 
PCA BIPLOTS FOR SAMPLE AND SNP REDUCTION  
 
Figure 1. Reducing Sample Size for Second Set of 100 Individuals 
A.  
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 C. 
 
Repeat of the reduction in sample size with the second set of 100. A. This biplot has 100 
individuals with 39,177 SNPs using a p-value of 0.05 as the threshold. There were 2 
outliers removed. B. This biplot has 50 individuals with 37,205 SNPs using a p-value of 
0.05 as the threshold.  C. This biplot has 20 individuals with 30,945 SNPs using a p-value 
of 0.05 as the threshold. In all biplots, green is case and control is blue. 
 
 
Figure 2. Reducing Sample Size for Third Set of 100 Individuals 
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 B. 
 
 C. 
 
Repeat of the reduction of sample size with the third set of 100. A. This biplot has 100 
individuals with 37,959 SNPs using a p-value of 0.05 as the threshold. There was 1 
outlier removed. B. This biplot has 50 individuals with 37,189 SNPs using a p-value of 
0.05 as the threshold. There was 1 outlier removed. C. This biplot has 20 individuals with 
30,223 SNPs using a p-value of 0.05 as the threshold. In all biplots, green is case and 
control is blue.
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Figure 3. Reducing Number of SNPs for Second Set of 100 Samples 
A.  
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C. 
 
PCA biplots are of second set of 100 samples with case green and control blue. There 
were 2 outliers removed from all plots. A. The p-value is 5 x 10-3 as the threshold giving 
3,483 SNPs for PCA analysis. Two samples were removed as outliers. B. P-value of 5 x 
10-4 as the threshold with 316 SNPs. C. P-value of 5 x 10-5 as the threshold with 45 SNPs. 
Separation of case and control is mostly maintained for all reduction of SNPs.  
 
 
Figure 4. Reducing Number of SNPs for Second Set of 50 Samples 
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B. 
 
 C. 
 
PCA biplots are of 50 samples with case green and control blue. A. The p-value is 5 x 10-3 as the threshold giving 3,220 SNPs for PCA analysis. B. P-value of 5 x 10-4 as the 
threshold with 235 SNPs. C. P-value of 5 x 10-5 as the threshold with 14 SNPs. 
Separation of case and control is maintained for all reduction of SNPs. 
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Figure 5. Reducing Number of SNPs for Second Set of 20 Samples 
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C. 
 
PCA biplots are of 20 samples with case green and control blue. A. The p-value is  5 x 
10-3 as the threshold giving 2,396 SNPs for PCA analysis. B. P-value of 5 x 10-4 as the 
threshold with 169 SNPs. C. P-value of 5 x 10-5 as the threshold with 6 SNPs. Separation 
of case and control is mostly maintained for all reduction of SNPs. 
 
 
Figure 6. Reducing Number of SNPs for Third Set of 100 Samples 
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B. 
 
 C.  
 
PCA biplots are of 100 samples with case green and control blue. There were 2 outliers 
removed from all plots. A. The p-value is 5 x 10-3 as the threshold giving 3,190 SNPs for 
PCA analysis. B. P-value of 5 x 10-4 as the threshold with 248 SNPs. C. P-value of 5 x 
10-5 as the threshold with 19 SNPs. Separation of case and control is mostly maintained 
for all reduction of SNPs. 
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Figure 7. Reducing Number of SNPs for Third Set of 50 Samples 
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C. 
 
PCA biplots are of 50 samples with case green and control blue. A. The p-value is 5 x 10-3 as the threshold giving 3,136 SNPs for PCA analysis. B. P-value of 5 x 10-4 as the 
threshold with 234 SNPs. C. P-value of 5 x 10-5 as the threshold with 24 SNPs. 
Separation of case and control is maintained for all reduction of SNPs.  
 
 
Figure 8. Reducing Number of SNPs for Third Set of 20 Samples 
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B. 
 
 C. 
 
PCA biplots are of 20 samples with case green and control blue. A. The p-value is  5 x 
10-3 as the threshold giving 2,342 SNPs for PCA analysis. B. P-value of 5 x 10-4 as the 
threshold with 162 SNPs. C. P-value of 5 x 10-5 as the threshold with 5 SNPs. Separation 
of case and control is maintained for all reduction of SNPs.  
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